ICH E14 Q & A (R1) document: perspectives on the updated recommendations on thorough QT studies

Authors

  • Rashmi R. Shah,

    Corresponding author
    • Rashmi Shah Consultancy Ltd, Gerrards Cross, UK
    Search for more papers by this author
    • The views expressed in this paper are those of the authors and do not necessarily reflect the views or opinions of their affiliates, any regulatory authorities or any of their advisory bodies.
  • Joel Morganroth

    1. eResearch Technology, Philadelphia, PA, USA
    Search for more papers by this author

CORRESPONDENCE

Dr Rashmi R. Shah, 8 Birchdale, Gerrards Cross, Buckinghamshire SL9 7JA, UK.

Tel.: +44 1753 886348

E-mail: clinical.safety@hotmail.co.uk

Abstract

The International Conference on Harmonization (ICH) guidance ICH E14 provides recommendations, focusing on a clinical ‘thorough QT/QTc (TQT) study’, to evaluate the QT liability of a drug during its development. An Implementation Working Group (IWG) was also established to assist the sponsors with any uncertainties and clarify any ambiguities. In April 2012, the IWG updated its June 2008 version of the Questions and Answers document to address additional issues. These include the gender of the study population, a reasonable approach to evaluating QTc changes in late stage clinical development and the recommended approach to correcting the measured QT interval. This commentary provides our observations and, when appropriate, recommendations, on these issues. We review briefly evidence that suggests that (i) the greater QT effect observed in females is not entirely related to differences in drug exposure and (ii) the Fridericia correction of measured QT interval is adequate for a majority of TQT studies. Until further evidence suggests otherwise, we recommend balanced gender representation in TQT studies, unless warranted otherwise, and for positive studies, subgroup analysis of key data by common demographic variables including the gender and ethnicity. We provide a general scheme for ECG monitoring in late phase clinical trials and consider that while intensive monitoring and centralized reading of ECGs in late phase clinical trials is the norm when a TQT study is positive, there are other circumstances that also call for high quality ECG reading. Therefore, locally read ECGs should only be acceptable as long as accurate high quality ECG data can be guaranteed.

Ancillary